Anat Kerem-Angel

Finance

Health Technology

Consumer Services

Profile

Anat Kerem-Angel served as a Director at Thrombotech Ltd.
She also worked as an Associate at Youdim Pharmaceuticals Ltd.
from 2004 to 2010.
Dr. Kerem-Angel holds a doctorate degree from Tel-Aviv University.

Former positions of Anat Kerem-Angel

Companies	Position	End
Youdim Pharmaceuticals Ltd. Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel.	Private Equity Investor	30/12/2010
Thrombotech Ltd. Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.	Director/Board Member	-

See the detail of Anat Kerem-Angel's experience

Training of Anat Kerem-Angel

Tel-Aviv University

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Anat Kerem-Angel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Youdim Pharmaceuticals Ltd. Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel.	Finance
Thrombotech Ltd. Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.	Health Technology